XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (60,566) $ (81,669)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,126 3,028
Stock-based compensation expense 9,032 10,323
Net (accretion) amortization of (discount) premium on marketable securities (1,675) 258
Non-cash lease expense 6,936 2,234
Loss on disposal of property and equipment 0 101
Impairment of long-lived assets 0 2,011
Other (306) (76)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 775 (4,165)
Other assets 105 (3,403)
Accounts payable (944) 3,216
Accrued expenses and other liabilities (525) 2,134
Lease liability and lease incentive receivable (1,619) 8,200
Net cash used in operating activities (45,661) (57,808)
Cash flows from investing activities:    
Purchases of marketable securities (20,232) (57,674)
Maturities of marketable securities 108,909 183,599
Purchases of property and equipment (121) (10,807)
Net cash provided by investing activities 88,556 115,118
Cash flows from financing activities:    
Proceeds from issuance of common stock pursuant to option exercises 0 3
Payment of deferred offering costs (238) 0
Proceeds from employee stock purchase plan 246 362
Net cash provided by financing activities 8 365
Net increase in cash and cash equivalents and restricted cash 42,903 57,675
Cash and cash equivalents and restricted cash at beginning of period 70,934 36,698
Cash and cash equivalents and restricted cash at end of period 113,837 94,373
Cash and cash equivalents 111,187 91,870
Restricted cash 2,650 2,503
Cash and cash equivalents and restricted cash at end of period 113,837 94,373
Supplemental schedule of noncash investing and financing information    
Remeasurement of operating lease right-of-use assets 13,711 0
Fixed assets in accounts payable, accrued expenses and other current liabilities 496 908
Deferred offering costs included in accounts payable $ 107 $ 0